No Data
Resumed trading with a one-character limit up, cabio biotech(wuhan) intends to acquire 65% equity of Eurobio symbol company with high debts.
1. Eurobio achieved a turnaround in profitability starting in 2023. From the first three quarters of 2022 to 2024, the target company achieved revenues of 0.265 billion yuan, 0.309 billion yuan, and 0.267 billion yuan respectively; 2. Xinda Securities stated that considering the closely related multiple group testing of the target company with cabio biotech(wuhan)'s existing synthetic biology research and development, it is expected that the two will form a strong synergistic effect.
Cabio Biotech(Wuhan) (688089.SH): intends to acquire 65.00% equity of EU Bio from November 12 and will resume trading.
On November 11th, Cabio Biotech (wuhan) (688089.SH) announced that the company plans to purchase 65.00% equity of Ouyi Biotech from 14 trading partners including Wang Shuwei, Dong Dong, Xiao Yunping, Wang Xiuping, Jin Chao, Shi Xianjun, Shanghai Fanyi, Ningbo Ruio, Ningbo Ouren, National Pharmaceutical Phase II, Nantong Dongzheng, Suzhou Dingshi, Shanghai Biology, Shanghai Shengqi, through the issuance of shares and cash payment, and raise supporting funds. The final transaction price of the target assets will be based on the evaluation results of the evaluation report issued by the asset evaluation institution in accordance with the Securities Law, and will be determined through full negotiation between the two parties. The target company consists of multiple
Cabio Biotech (Wuhan) (688089.SH) is planning a major asset restructuring, and the stocks will continue to be suspended from trading.
cabio biotech(wuhan) (688089.SH) announced that the company is planning to purchase shanghai through the issuance of shares and payment of cash...
Cabio Biotech(Wuhan) (688089): Q3 profits under short-term pressure, planning assets restructuring.
Event: The company released the third quarter report for 2024. In 2024 Q1-3, the company achieved revenue of 0.387 billion yuan, a year-on-year increase of +19.19%; net income attributable to the parent company was 83.89 million yuan, a year-on-year increase of +38.86%; after-tax net income attributable to the parent company
Express News | Three mergers in a single day! The merger and reorganization market remains active, showing four major new trends.
cabio biotech(wuhan) (688089): Seize the opportunity of layout and plan to acquire equity of Europe easy.
Announcement of the company's 2024 third quarter report. In the first three quarters of 2024, the company achieved a total revenue of 0.387 billion yuan (+19.19%), a net profit attributable to the parent company of 0.084 billion yuan (+38.86%), and a non-GAAP net profit of 0.
No Data
No Data